King of Prussia, PA – October 23rd, 2024: CluePoints, provider of leading statistical and AI-driven software solutions, has been recognized for its impressive growth at the BVA Private Equity Awards.
CluePoints won Growth Company of the Year at the 2024 edition of the awards. The award recognized CluePoints as a stand-out business, with skilled project execution, authentic leadership and outstanding overall growth. The judges also recognized the company’s commitment to Environmental and Social Governance (ESG) and its contribution to improving outcomes for patients worldwide.
Commenting on the accolade, Andy Cooper, CEO at CluePoints said: “CluePoints’ mission is to help customers bring new therapies to market faster for the benefit of patients globally. We do this by enabling our customers to run smarter clinical trials by providing best-in-class statistical and AI-driven software solutions to enable the Life Science industry to focus on what matters most. In 2024, CluePoints made the transition from a single-product company to a multi-product platform company. This award is valued recognition for our fantastic team members who have been driving the launch of new products and helping to turn artificial intelligence into human intelligence.”
CluePoints was founded in 2012. Following a financing round by Summit in 2020, it was acquired by EQT in 2024, with WE, Invest.BQ and Theodorus making a successful exit. Since becoming a multi-product platform, it has launched new products including SPOT (Site Profile and Oversight Tool), Intelligent Medical Coding (IMC), and Medical & Safety Review (MSR).
Jan Alexander, Secretary General of the BVA said: “CluePoints’ submission demonstrated incredibly impressive growth – both financially and in its product portfolio. What also impressed the judging panel was CluePoints’ outstanding commitment to improving outcomes for patients globally and upholding high ESG standards.”
For further information on CluePoints’ solutions visit cluepoints.com/what-we-do
About CluePoints
CluePoints is the premier Risk-Based Quality Management (RBQM) and Data Quality Oversight Software provider. We are leveraging the potential of Artificial Intelligence using Advanced Statistics and Machine Learning to determine the quality, accuracy, and integrity of clinical trial data both during and after study conduct. Aligned with guidance from the FDA, EMA, and ICH E6 (R2), CluePoints is deployed to support central and on-site monitoring, medical review, quality risk management and to drive a holistic Risk-Based strategy in all trials. Coupled with thought leadership and consulting expertise to aid pre-study risk assessment, identification of risk controls and solution implementation, you now have everything you need to adhere with global regulatory guidance. The result is positive clinical development outcomes, increased operational efficiency, lower costs and reduced regulatory submission risk as part of the industry paradigm shift to RBQM.
Media Contact
Jodie Dixon – Discovery PR, on behalf of CluePoints
Email: [email protected]
Mobile: +44 (0)7507 727721
Office: +44 (0) 1606 889 194
